SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN)

REGENERON PHARMACEUTICALS, INC. · ANALYST-DOWNGRADE filed

At the news

BEARISHIMPACT 2/10

ANALYST-DOWNGRADE filed

On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price target from $900 to $700, nearly in line with the current $698.25. Leerink Partners downgraded from Outperform to Market Perform with a $641 target, implying ~8% downside. Both firms have below-average track records on REGN (Citi 43% accuracy on 7 calls, Leerink 50% on 2 calls). Consensus remains strongly bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, with a mean price target of $875.31 (25.4% upside). EPS revision momentum is positive, with 15 upgrades vs 6 downgrades for the next quarter. Insider sales are small and routine; institutional activity is mixed (Two Sigma trimming but Norges Bank adding a $1B position). While the cluster downgrade signals near-term caution, the positive consensus and earnings momentum suggest the stock may find support near $700. The low accuracy of the downgrading firms reduces the significance of this action.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access